Ustekinumab

證據等級: L5

預測適應症: 10 個

Ustekinumab: From Plaque Psoriasis to Dermatitis

One-Sentence Summary

Ustekinumab is a monoclonal antibody originally developed for plaque psoriasis and related inflammatory conditions (general background knowledge; the evidence pack contains no confirmed original-indication or license text). The TxGNN model predicts it may be effective for Dermatitis (evidence points specifically toward atopic dermatitis), with 7 clinical trials currently supporting this direction and no published literature yet identified.

Quick Overview

Item	Content
Original Indication	Not available in evidence pack (drug is unlicensed in NZ; `original_indications` empty). Publicly known original use: plaque psoriasis/psoriatic arthritis.
Predicted New Indication	Dermatitis (atopic dermatitis)
TxGNN Prediction Score	99.99%
Evidence Level	L2
New Zealand Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data from the drug record itself is marked as a data gap. However, based on the repurposing rationale attached to this prediction, ustekinumab's known pharmacology is an anti-IL-12/23 p40 monoclonal antibody that blocks the Th1/Th17 inflammatory pathway.

Psoriasis-family disease is strongly Th17-driven, and IL-12/23 blockade has well-established efficacy there — several trials in the evidence set (e.g., the CLEAR trial, NCT02074982) use ustekinumab as an active comparator in plaque psoriasis. Atopic dermatitis, by contrast, is primarily a Th2-driven disease, so the mechanistic link to "dermatitis" as predicted here is comparatively indirect. This raises a specific caution: the TxGNN score may be inflated by ustekinumab's strong association with psoriasis-spectrum disease being folded into the broader "dermatitis" concept, rather than reflecting confirmed efficacy in atopic dermatitis specifically.

The one directly relevant trial (NCT01806662) tested ustekinumab in chronic atopic dermatitis patients with sub-optimal response to prior therapy and completed with n=32 — supportive but small and pilot-scale, not yet sufficient to establish efficacy independently of the psoriasis mechanistic assumption.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01806662	Phase 2	Completed	32	Randomized pilot study of ustekinumab in chronic atopic dermatitis with sub-optimal response to prior therapy — the only trial directly testing ustekinumab in an atopic-dermatitis-labeled population.
NCT01945086	Phase 2	Completed	79	Randomized, double-blind, placebo-controlled ustekinumab trial in adult Japanese subjects with severe atopic dermatitis.
NCT05535738	Phase 2/3	Recruiting	45	Contact dermatitis suction-blister model studying skin inflammation with biologic therapies; ustekinumab's specific inclusion is unconfirmed.
NCT02074982	Phase 3	Completed	676	CLEAR trial: secukinumab vs. ustekinumab in moderate-to-severe plaque psoriasis (ustekinumab as active comparator, not the test drug for dermatitis).
NCT07352566	Phase 4	Not yet recruiting	10	Cutaneous microdevice testing FDA-approved atopic dermatitis/psoriasis drugs in situ; drug-to-indication mapping unclear.
NCT01356758	N/A	Completed	126	Observational cardiovascular risk assessment in severe psoriasis patients on biologics; indirect safety signal only.
NCT07041112	N/A	Completed	1000	Retrospective pharmacogenetic study on biologic therapy survival in cutaneous psoriasis; not a dermatitis efficacy study.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information. A blocking data gap (DG001: TFDA/regulatory package-insert warnings and contraindications) currently prevents this candidate from entering the S1 safety evaluation stage.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence level is L2 on the strength of one completed but small Phase 2 pilot RCT (n=32) directly testing ustekinumab in atopic dermatitis, and the mechanistic link is plausible but indirect (Th17-oriented drug applied to a largely Th2-driven disease). More critically, a Blocking-severity data gap (missing TFDA/package-insert safety data) prevents this candidate from clearing initial safety evaluation (S1), so a Go or Guardrailed-Proceed decision cannot be responsibly made yet.

To proceed, the following is needed:

TFDA/regulatory package insert (warnings, contraindications) to clear the blocking S1 safety gate
Confirmed mechanism-of-action documentation from DrugBank to validate the Th17-vs-Th2 mechanistic concern
Clarification of whether "dermatitis" evidence reflects atopic dermatitis specifically or is conflated with psoriasis-spectrum trials
A larger, adequately powered trial beyond the existing n=32 pilot before advancing past the research-question stage
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.